These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 18565393)

  • 1. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
    Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2010 Apr; 11(5):723-30. PubMed ID: 20210681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic dyslipidemia: a practical guide to therapy.
    Tovar JM; Bazaldua OV; Loffredo A
    J Fam Pract; 2008 Jun; 57(6):377-88. PubMed ID: 18544321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H
    Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
    Shoji T; Nishizawa Y
    Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia in chronic kidney disease: managing a high-risk combination.
    Chauhan V; Vaid M
    Postgrad Med; 2009 Nov; 121(6):54-61. PubMed ID: 19940417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with statins and omega-3 fatty acids.
    Nambi V; Ballantyne CM
    Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
    Schima SM; Maciejewski SR; Hilleman DE; Williams MA; Mohiuddin SM
    Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
    Kastelein JJ
    Am J Cardiol; 2005 Nov; 96(9A):20K-27K; discussion 34K-35K. PubMed ID: 16291010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.